Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Current Assets (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Current Assets for 12 consecutive years, with $442.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 3.14% to $442.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $442.7 million, a 3.14% decrease, with the full-year FY2025 number at $442.7 million, down 3.14% from a year prior.
  • Current Assets was $442.7 million for Q4 2025 at Iovance Biotherapeutics, up from $429.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $637.8 million in Q1 2023 to a low of $274.9 million in Q2 2023.
  • A 3-year average of $425.3 million and a median of $425.8 million in 2025 define the central range for Current Assets.
  • Biggest YoY gain for Current Assets was 48.46% in 2024; the steepest drop was 39.55% in 2024.
  • Iovance Biotherapeutics' Current Assets stood at $307.8 million in 2023, then surged by 48.46% to $457.0 million in 2024, then fell by 3.14% to $442.7 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Current Assets are $442.7 million (Q4 2025), $429.1 million (Q3 2025), and $422.5 million (Q2 2025).